A systems biology approach to the global analysis of transcription factors in colorectal cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Pradhan, Meeta P ^a   Prasad, Nagendra K A ^b   Palakal, Mathew J ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON REGULATORY FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SLUG;

ARTICLE; COLORECTAL CANCER; DATA MINING; DNA DAMAGE; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; INFORMATION RETRIEVAL; PROTEIN PROTEIN INTERACTION; SYSTEMS BIOLOGY;

COLORECTAL NEOPLASMS; DATA MINING; GENE EXPRESSION PROFILING; HUMANS; SYSTEMS BIOLOGY; TRANSCRIPTION FACTORS;

EID: 84864397277     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-331     Document Type: Article

References (140)

1. Tian L, et al. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A 2005, 102(38):13544-13549.
2. Dreyfuss JM, Johnson MD, Park PJ. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Molecular Cancer 2009, 8(71).
3. Herman JG, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998, 95(12):6870-6875.
4. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007, 21(20):2525-2538.
5. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nature Genetics 2003, 33(Suppl):228-237.
6. Kohler S, et al. Walking the interactome for prioritization of candidate disease genes. American Journal of Human Genetics 2008, 82(4):949-958.
7. Goh KI, et al. The human disease network. Proc Natl Acad Sci U S A 2007, 104(21):8685-8690.
8. Oti M, et al. Predicting disease genes using protein-protein interactions. Journal of Medical Genetics 2006, 43(8):691-698.
9. Karni S, Soreq H, Sharan R. A Network-Based Method for Predicting Disease-Causing Genes. Journal of Computational Biology 2009, 16(2):181-189.
10. Tranchevent LC, et al. A guide to web tools to prioritize candidate genes. Brief Bioinform 2011, 12(1):22-32.
11. Feldman I, Rzhetsky A, Vitkup D. Network properties of genes harboring inherited disease mutations. Proc Natl Acad Sci U S A 2008, 105(11):4323-8.
12. Xu JZ, Li YJ. Discovering disease-genes by topological features in human protein-protein interaction network. Bioinformatics 2006, 22(22):2800-2805.
13. Wu X, et al. Network-based global inference of human disease genes. Mol Syst Biol 2008, 4:189.
14. Chen Y, Jiang T, Jiang R. Uncover disease genes by maximizing information flow in the phenome-interactome network. Bioinformatics 2011, 27(13):I167-I176.
15. Nitsch D, et al. Candidate gene prioritization by network analysis of differential expression using machine learning approaches. BMC Bioinformatics 2010, 11:460.
16. Chen JL, et al. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. Journal of the American Medical Informatics Association 2011, 18(4):392-402.
17. Engreitz JM, et al. Content-based microarray search using differential expression profiles. BMC Bioinformatics 2010, 11:603.
18. Miozzi L, Piro RM, Rosa F, Ala U, Silengo L, Di Cunto F, Provero P. Functional Annotation and Identification of Candidate Disease Genes by Computational Analysis of Normal Tissue Gene Expressio. PLOs One 2008, 3(6):e2439.
19. Kohler S, et al. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 2008, 82(4):949-958.
20. Uzgur A, et al. Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics 2008, 24(13):I277-I285.
21. Gonzalez G, et al. Mining gene-disease relationships from biomedical literature: weighting protein-protein interactions and connectivity measures. Pac Symp Biocomput 2007, 28-39.
22. Yu S, et al. Gene prioritization and clustering by multi-view text mining. BMC Bioinformatics 2010, 11:28.
23. Waagmeester A, et al. Pathway Enrichment Based on Text Mining and Its Validation on Carotenoid and Vitamin A Metabolism. Omics-a Journal of Integrative Biology 2009, 13(5):367-379.
24. Yu S, et al. Gene prioritization and clustering by multi-view text mining. BMC Bioinformatics 2010, 11:28.
25. Aerts S, et al. Gene prioritization through genomic data fusion (vol 24, pg 537, 2006). Nature Biotechnology 2006, 24(6):719-719.
26. Liekens AM, et al. BioGraph: unsupervised biomedical knowledge discovery via automated hypothesis generation. Genome Biology 2011, 12(6):R57.
27. Mullen AC, Orlando DA, Newmann JJ, Lovén J, Kumar RM, Bilodeau S, Guenther MG, Reddy J, DeKoter RP, Young RA. Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-beta Signaling. CELL 2011, 147(3):565-576.
28. Osorio KM, Lilja KC, Tumbar T. Runx1 modulates adult hair follicle stem cell emergence and maintenance from distinct embryonic skin compartments. Journal of Cell Biology 2011, 193(1):235-250.
29. Luscombe NM, et al. Genomic analysis of regulatory network dynamics reveals large topological changes. Nature 2004, 431(7006):308-312.
30. Kondo E, Horii A, Fukushige S. The interacting domains of three MutL heterodimers in man: hMLH1 interacts with 36 homologous amino acid residues within hMLH3, hPMS1 and hPMS2. Nucleic Acids Res 2001, 29(8):1695-1702.
31. Lipkin S, et al. MLH3: A novel DNA mismatch repair gene associated with mammalian microsatellite instability and a colon cancer susceptibility locus in the mouse. Nature Genetics 2000, 24(1):27-35.
32. Nassif NT, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004, 23(2):617-628.
33. Sawai H, et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. Bmc Gastroenterology 2008, 8:56.
34. Liu W, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat. Genet. 2000, 26(2):146-147.
35. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 1996, 49(7):560-564.
36. Cunningham MP, et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol. 2006, 28(2):329-335.
37. Hsieh JS, et al. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 2005, 71(4):336-343.
38. Darnell JE. Transcription factors as targets for cancer therapy. Nature Reviews Cancer 2002, 2(10):740-749.
39. Seican R, Funariu G, Seicean A. Molecular prognostic factors in colorectal cancer. Romanian Journal of Gastroenterology 2004, 13(3):223-231.
40. Anderson CL, et al. Dyregulaiton of the transcription factors SOX4, CBFB and SMARCC1 correlated with outcome of colorectal cancer. British Journal of Cancer 2009, 100:511-523.
41. Palakal MJ, et al. Identification of biological relationships from text documents using efficient computational methods. J. Bioinformatics and Computational Biology 2003, 1(2):307-342.
42. Martin D, et al. GOToolBox: functional analysis of gene datasets based on Gene Ontology. Genome Biol 2004, 5(12):R101.
43. Pradhan MP, Gandra P, Palakal MP. Predicting protein-protein interactions using first principle methods and statistical scoring 2010, India, Proceedings of International Symposium on Bio Computing, ISB, Calicut.
44. Barabasi AL, Bonabeau E. Scale-free networks. Sci Am 2003, 288(5):60-69.
45. Milenkovic T, et al. Systems-level cancer gene identification from protein interaction network topology applied to melanogenesis-related functional genomics data. J R Soc Interface 2010, 7(44):423-437.
46. Kuchaiev O, et al. Topological network alignment uncovers biological function and phylogeny. J R Soc Interface 2010, 7(50):1341-1354.
47. Lubovac Z, Gamalielsson J, Olsson B. Combining functional and topological properties to identify core modules in protein interaction networks. Proteins 2006, 64(4):948-959.
48. Cho Y-R, Hwang W, Zhang A. Modularization of protein interaction networks by incorporating gene ontology annotations (CIBCB) 2007, 233-238. Proceedings of the 2007 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology.
49. Park J, Lappe M, Teichmann SA. Mapping protein family interactions: intramolecular and intermolecular protein family interaction repertoires in the PDB and yeast. J Mol Biol 2001, 307(3):929-938.
50. Peri S, et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Research 2003, 13(10):2363-2371.
51. Hall M, et al. The WEKA Data Mining Software: An Update. SIGKKD Explorations 2009, 11(1):10-18.
52. Samanta MP, Laing S. Predicting protein functions from redundancies in large scale protein interaction network. PNAS 2003, 100(22):12579-12583.
53. Milenkovic T, et al. Systems-level cancer gene identification from protein interaction network toplogy applied to melanogenesis-related funcitonal genomics data. J.R.Soc. Interface 2009, 7:423-437.
54. Ho H, et al. Protein interaction network topology uncovers melanogenesis regulatory network components within functional genomics datasets. BMC System Biology 2010, 4(84).
55. Carugo O. Objective definition of interaction degree between residues in globular proteins. Journal of Molecular structure. TheoChem 2004, 676(1-3):161-164.
56. Thornton JM, et al. Protein-protein recognition via side-chain interactions. Biochem Soc Trans 1988, 16(6):927-930.
57. Shama J, et al. Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. Biochem Biophys Res Commun 2008, 372(4):845-859.
58. Fang JU, Richardson BC. The MAPK signaling pathways and colorectal cancer. The Lancet Oncology 2005, 6(5):322-327.
59. Zhu F, et al. Involvement of ERKs and mitogen- and stress-activated protein kinase in UVC-induced phosphorylation of ATF2 in JB6 cells. Carcinogenesis 2004, 25(10):1847-1852.
60. Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005, 57(4-5):283-295.
61. Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990, 87(19):7555-7559.
62. Yamaguchi A, et al. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 1993, 68:399-402.
63. Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004, 25(11):2183-2189.
64. Collett GP, Campbell FC. Overexpression of p65/ReIA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2006, 27(6):1285-1291.
65. Lin Q, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005, 167(4):969-980.
66. Kusaba T, Nakayama T, Yamazumi K, et al. Activation of STAT3 is a marker of poor prognosis in human colorectalcancer. ONCOLOGY REPORTS 2006, 14:1445-1451.
67. Slattery ML, et al. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 2007, 18(10):1095-1105.
68. Bian YH, et al. Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J Gastroenterol 2007, 13(11):1659-1665.
69. Akiyoshi T, et al. Gli1, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. GUT 2006, 55(7):991-999.
70. Coppola D, et al. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol 2009, 135(9):1287-1291.
71. Douard R, et al. Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery 2006, 139(5):665-670.
72. Mauro MJ, Druker BJ. STI571: Targeting BCR-ABL as therapy for CML. Oncologist 2001, 6(3):233-238.
73. Vlahopoulos SA, et al. The role of ATF-2 in oncogenesis. Bioessays 2008, 30(4):314-27.
74. Lee SH, et al. Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene 2010, 29(37):5182-5192.
75. Voutsadakis IA. Peroxisome proliferator activated receptor-gamma and the ubiquitin-proteasome system in colorectal cancer. World J Gastrointest Oncol 2010, 2(5):235-241.
76. Wang D, et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor. Cancer Cell 2004, 6(3):285-295.
77. Guo YS, et al. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J Biol Chem 2002, 277(50):48755-48763.
78. Baba Y, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancer. American Journal of Pathology 2010, 176(5):2292-2301.
79. Akiyama Y, et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 2003, 23(23):8429-8439.
80. Miao H, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nature Cell Biology 2001, 3(5):527-530.
81. Herath NI, Boyd AW. The role of Eph receptors and ephrin ligands in colorectal cancer. International Journal of Cancer 2010, 126(9):2003-2011.
82. Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007, 50(1):131-150.
83. Karin M, Gallagher E. From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005, 57(4-5):283-295.
84. Terzic J, et al. Inflammation and Colon Cancer. Gastroenterology 2010, 138(6):2101-U119.
85. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews Cancer 2009, 9(8):537-549.
86. Vivas-Mejia P, et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clinical Cancer Research 2010, 16(1):184-194.
87. Kaoud TS, et al. Development of JNK2-Selective Peptide Inhibitors that Inhibit Breast Cancer Cell Migration. ACS Chem. Biol. 2011, 6(6):658-666.
88. Das M, et al. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011, 25(6):634-645.
89. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26(22):3291-3310.
90. Whitmarsh AJ, et al. Integration of Map Kinase Signal-Transduction Pathways at the Serum Response Element. Science 1995, 269(5222):403-407.
91. Waetzig V, Herdegen T. The concerted signaling of ERK1/2 and JNKs is essential for PC12 cell neuritogenesis and converges at the level of target proteins. Molecular and Cellular Neuroscience 2003, 24(1):238-249.
92. Mohney RP, et al. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. Journal of Biological Chemistry 2003, 278(47):47038-47045.
93. Whitmarsh AJ, et al. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995, 21(269(5222)):403-407.
94. Slattery ML LA, Herrick JS, Caan BJ, Potter JD, Wolff RK. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-β-signaling pathway. Carcinogenesis 2011, 32(3):318-326.
95. Duda DG, et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin Cancer Res 2011, 17(8):2074-2080.
96. Gross V, et al. Regulation of Interleukin-8 Production in a Human Colon Epithelial-Cell Line (Ht-29). Gastroenterology 1995, 108(3):653-661.
97. Janakiram NB, Rao CV. Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer. Current Molecular Medicine 2009, 9(5):565-579.
98. Glasl S, et al. Novel germline mutation (300305delAGTTGA) in the human MSH2 gene in herediatery nonpolyposis colorectal cancer. Human Mutation 2000, 16(1):9192.
99. Balaguer F, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 2007, 5(3):379-387.
100. Firestein R, et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature 2008, 455:547-551.
101. Firestein R, et al. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. International Journal of Cancer 2010, 126(12):2863-2873.
102. Forcet C, et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. PNAS 2001, 98(6):3416-3421.
103. Zeng QH, et al. Tgfbr1 Haploinsufficiency Is a Potent Modifier of Colorectal Cancer Development. Cancer Research 2009, 69(2):678-686.
104. Carvajal-Carmona LG, et al. Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition. PNAS 2010, 107(17):7858-7862.
105. Ceol CJ, Pellman D, Zon LI. APC and colon cancer: two hits for one. Nat Med 2007, 13(11):1286-1287.
106. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009, 656:85-106.
107. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009, 361(1):98-99.
108. Tran B, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011,
109. Offit K. MSH6 mutations in hereditary nonpolyposis colon cancer: Another slice of the pie. Journal of Clinical Oncology 2004, 22(22):4449-4451.
110. Kolodner RD, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Research 1999, 59(20):5068-5074.
111. Brand S, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 2005, 310(1):117-130.
112. Kanzaki H, et al. Single nucleotide polymorphism in the RAD18 gene and risk of colorectal cancer in the Japanese population. Oncol Rep 2007, 18(5):1171-1175.
113. Yang KL, Moldovan GL, D'Andrea AD. RAD18-dependent Recruitment of SNM1A to DNA Repair Complexes by a Ubiquitin-binding Zinc Finger. Journal of Biological Chemistry 2010, 285(25):19085-19091.
114. Direnzo MF, et al. Overexpression and Amplification of the Met/Hgf Receptor Gene during the Progression of Colorectal-Cancer. Clinical Cancer Research 1995, 1(2):147-154.
115. Otte JM, et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000, 61(4):237-246.
116. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med 2009, 1(4):36.
117. Park HJ, et al. Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4. Phytomedicine 2008, 15(1-2):147-151.
118. Soung YH, et al. Somatic mutations of CASP3 gene in human cancers. Human Genetics 2004, 115(2):112-115.
119. Oh JE, et al. Mutational analysis ofCASP10gene in colon, breast, lung and hepatocellular carcinomas. Pathololgy 2010, 42(1):73-76.
120. Bell DA, et al. Polyadenylation Polymorphism in the Acetyltransferase-1 Gene (Nat1) Increases Risk of Colorectal-Cancer. Cancer Research 1995, 55(16):3537-3542.
121. Katoh T, et al. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. International Journal of Cancer 2000, 85(1):46-49.
122. Economopoulos KP, Sergentanis TN. GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: A comprehensive meta-analysis. European Journal of Cancer 2010, 46(9):1617-1631.
123. Martinez C, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk - Response. Carcinogenesis 2002, 23(4):667-668.
124. Martinez C, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 2001, 22(8):1323-1326.
125. Poincloux L, et al. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surgical Oncology-Oxford 2009, 18(4):357-365.
126. Mathioudaki K, et al. The PRMT1 gene expression pattern in colon cancer. British Journal of Cancer 2008, 99(12):2094-2099.
127. Mathioudaki K, Scorilas A, Talieri M. Expression pattern of protein arginine methyltransferase 1 gene (PRMT1) in breast and colon cancer. Febs Journal 2008, 275:414-414.
128. Slattery ML, et al. Genetic Variation in the TGF-beta Signaling Pathway and Colon and Rectal Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2011, 20(1):57-69.
129. Wei EK, et al. A prospective study of C-peptide, insulin-like growth factor-1, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiology Biomarkers & Prevention 2005, 14(4):850-855.
130. Nakamura Y, et al. PDGF-BB is a novel prognostic factor in colorectal cancer. Annals of Surgical Oncology 2008, 15(8):2129-2136.
131. Sillars-Hardebol AH, et al. Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumor Biology 2010, 31(2):89-96.
132. Weichert W, et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005, 28(11):5644-5650.
133. Liu YH, et al. Detection of interferon-induced transmembrane-1 gene expression for clinical diagnosis of colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28(11):1950-1953.
134. Gill S, Lindor NM, Burgart LJ, Smalley R, Leontovich O, French AJ, Goldberg RM, Sargent DJ, Jass JR, Hopper JL, Jenkins MA, Young J, Barker MA, Walsh MD, Ruszkiewicz AR, Thibodeau SN. Isolated loss of PMS2 expression in colorectal cancers frequency, patient age and familal aggregation. Clinical Cancer Research 2005, 11:6466-6471.
135. Doll D, et al. Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. International Journal of Colorectal Disease 2010, 25(5):573-581.
136. Peters G, et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Archiv 2003, 443(2):139-145.
137. Dong LM, et al. Vitamin D Related Genes, CYP24A1 and CYP27B1, and Colon Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2009, 18(9):2540-2548.
138. Matusiak D, Benya RV. CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. Journal of Histochemistry & Cytochemistry 2007, 55(12):1257-1264.
139. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004, 23(1-2):77-99.
140. Pradhan MP, Palakal MJ. Identifying CRC specific pathways and drug targets from literature augmeneted proteomics data. Proceedings of the BioCOMP 2010, II:323-330.